by Jennifer Stella
Several marketed vaccinations, including two Covid-19 vaccinations, are produced using human fetal tissue, including:
- Johnson & Johnson Covid-19 injection: produced in genetically modified human embryonic retinal cells (PER.C6 TetR).
- AstraZeneca Covid-19 injection: produced in genetically modified human embryonic kidney cells (HEK 293).
- Chicken pox vaccines (Proquad, Varivax and Zostavax): produced in human fetal lung tissue (MRC-5).
- Hepatitis A vaccines (Vaqta, Havrix, Twinrix): produced in human fetal lung tissue (MRC-5).
- MMR vaccines: produced in human fetal lung tissue (WI-38).
For a complete list of labeled vaccine ingredients, Johns Hopkins University publishes an up-to-date list, found here: https://www.vaccinesafety.edu/components-Excipients.htm.
Concerning the Moderna mRNA covid-19 injection: Moderna’s 2018 SEC filing clearly states that, “Currently, mRNA is considered a gene therapy product by the FDA. Unlike certain gene therapies that irreversibly alter cell DNA and could act as a source of side effects, mRNA based medicines are designed to not irreversibly change cell DNA; however, side effects observed in gene therapy could negatively impact the perception of mRNA medicines despite the differences in mechanism.”
In 2020, it was discovered/revealed that RNA has a direct effect on DNA stability, according to Professor Klungland. [Source: https://phys.org/news/2020-01-rna-effect-dna.html].
Also in 2020, Sanofi Pasteur (a giant pharmaceutical company based in Lyon, France) announced its abandonment of the MRC-5 fetal cell line in the development and production of its polio vaccine, Poliovax. Sanofi continues to produce the Imovax rabies vaccine: produced in human fetal lung tissue (MRC-5).
Also, the presence of fetal DNA fragment contaminants in injections has been linked to autism spectrum disorder. [See letter from Dr. Deisher, and paper: “Epidemiologic and molecular relationship between vaccine manufacture and autism spectrum disorder prevalence” at https://pubmed.ncbi.nlm.nih.gov/26103708/].
Jennifer Stella is co-director of Health Choice Vermont. She has a B.S. in Microbiology and experience in the development and global marketing of molecular diagnostic test technologies.